Oral Ketamine for Anxiety in Pancreatic Cancer
This study is looking at whether oral ketamine can help with anxiety in people with pancreatic cancer. You might be able to join if you have pancreatic cancer and are currently receiving or recently received cancer treatment. Participants will receive either ketamine or a placebo (an inactive substance) for four weeks, then switch after a break. The main goal is to see how easy it is to enroll people and if they stick with the treatment. Researchers will also look at how safe ketamine is and if it helps with anxiety, depression, pain, and other symptoms. This is a small study planning to enroll 20 people.
- Study design
- This is a double-blind, randomized, crossover study, meaning neither you nor your doctor will know if you are receiving ketamine or placebo at any given time. It plans to enroll 20 participants.
- What's involved
- You would take oral ketamine or placebo weekly for 4 weeks, followed by a 2-week break, and then switch to the other treatment for another 4 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at 2 months, which suggests the study will track participants for at least that long.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Scott Irwin, MD, PhD · PRINCIPAL_INVESTIGATOR · Cedars-Sinai Medical Center
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Feasibility of enrolling subjects which will be measured by the proportion of patients dropping out of study for any reason prior to the end of treatment visit.2 months
The following will be collected as part of this feasibility measurement: * Reasons for dropout. * Proportion of patients pre-screened that were potentially eligible for study participation. * Proportion of patients that were potentially eligible who were approached. * Proportion of approached patients that decline study participation and why. * Proportion of approached patients that agreed to participate. * Proportion of approached that were randomized. * Proportion of patients completing study through End of Treatment visit and each follow-up visit.